Mycosis fungoides and Sézary syndrome

Sam T. Hwang, John E. Janik, Elaine S. Jaffe, Wyndham H. Wilson

Research output: Contribution to journalReview article

171 Citations (Scopus)

Abstract

Mycosis fungoides and Sézary syndrome are the most common of the cutaneous T-cell lymphomas, which are a heterogeneous group of neoplasms that affect the skin as a primary site. Although the aetiologies of mycosis fungoides and Sézary syndrome are unknown, important insights have been gained in the immunological and genetic perturbations that are associated with these diseases. Unlike some B-cell lymphomas, cutaneous T-cell lymphomas as a group are rarely if ever curable and hence need chronic-disease management. New approaches to treatments are being investigated and include biological and cytotoxic drugs, phototherapy, and monoclonal antibodies that are directed towards novel molecular targets. New molecular technologies such as complementary-DNA microarray have the potential to increase the accuracy of diagnosis and provide important prognostic information. Treatments can be combined to greatly improve clinical outcome without substantially increasing toxic effects in advanced disease that is otherwise difficult to treat. Although present treatment strategies are generally not curative, there is hope that experimental treatments, particularly immunotherapy, might eventually reverse or suppress the abnormalities of mycosis fungoides and Sézary syndrome to the point at which they become non-life-threatening, chronic diseases.

Original languageEnglish (US)
Pages (from-to)945-957
Number of pages13
JournalThe Lancet
Volume371
Issue number9616
DOIs
StatePublished - Mar 18 2008

Fingerprint

Mycosis Fungoides
Cutaneous T-Cell Lymphoma
Chronic Disease
Phototherapy
Poisons
B-Cell Lymphoma
Skin Neoplasms
Therapeutics
Disease Management
Oligonucleotide Array Sequence Analysis
Immunotherapy
Complementary DNA
Monoclonal Antibodies
Technology
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hwang, S. T., Janik, J. E., Jaffe, E. S., & Wilson, W. H. (2008). Mycosis fungoides and Sézary syndrome. The Lancet, 371(9616), 945-957. https://doi.org/10.1016/S0140-6736(08)60420-1

Mycosis fungoides and Sézary syndrome. / Hwang, Sam T.; Janik, John E.; Jaffe, Elaine S.; Wilson, Wyndham H.

In: The Lancet, Vol. 371, No. 9616, 18.03.2008, p. 945-957.

Research output: Contribution to journalReview article

Hwang, ST, Janik, JE, Jaffe, ES & Wilson, WH 2008, 'Mycosis fungoides and Sézary syndrome', The Lancet, vol. 371, no. 9616, pp. 945-957. https://doi.org/10.1016/S0140-6736(08)60420-1
Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sézary syndrome. The Lancet. 2008 Mar 18;371(9616):945-957. https://doi.org/10.1016/S0140-6736(08)60420-1
Hwang, Sam T. ; Janik, John E. ; Jaffe, Elaine S. ; Wilson, Wyndham H. / Mycosis fungoides and Sézary syndrome. In: The Lancet. 2008 ; Vol. 371, No. 9616. pp. 945-957.
@article{bb0e86302fba484487493b14f2bc77bb,
title = "Mycosis fungoides and S{\'e}zary syndrome",
abstract = "Mycosis fungoides and S{\'e}zary syndrome are the most common of the cutaneous T-cell lymphomas, which are a heterogeneous group of neoplasms that affect the skin as a primary site. Although the aetiologies of mycosis fungoides and S{\'e}zary syndrome are unknown, important insights have been gained in the immunological and genetic perturbations that are associated with these diseases. Unlike some B-cell lymphomas, cutaneous T-cell lymphomas as a group are rarely if ever curable and hence need chronic-disease management. New approaches to treatments are being investigated and include biological and cytotoxic drugs, phototherapy, and monoclonal antibodies that are directed towards novel molecular targets. New molecular technologies such as complementary-DNA microarray have the potential to increase the accuracy of diagnosis and provide important prognostic information. Treatments can be combined to greatly improve clinical outcome without substantially increasing toxic effects in advanced disease that is otherwise difficult to treat. Although present treatment strategies are generally not curative, there is hope that experimental treatments, particularly immunotherapy, might eventually reverse or suppress the abnormalities of mycosis fungoides and S{\'e}zary syndrome to the point at which they become non-life-threatening, chronic diseases.",
author = "Hwang, {Sam T.} and Janik, {John E.} and Jaffe, {Elaine S.} and Wilson, {Wyndham H.}",
year = "2008",
month = "3",
day = "18",
doi = "10.1016/S0140-6736(08)60420-1",
language = "English (US)",
volume = "371",
pages = "945--957",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9616",

}

TY - JOUR

T1 - Mycosis fungoides and Sézary syndrome

AU - Hwang, Sam T.

AU - Janik, John E.

AU - Jaffe, Elaine S.

AU - Wilson, Wyndham H.

PY - 2008/3/18

Y1 - 2008/3/18

N2 - Mycosis fungoides and Sézary syndrome are the most common of the cutaneous T-cell lymphomas, which are a heterogeneous group of neoplasms that affect the skin as a primary site. Although the aetiologies of mycosis fungoides and Sézary syndrome are unknown, important insights have been gained in the immunological and genetic perturbations that are associated with these diseases. Unlike some B-cell lymphomas, cutaneous T-cell lymphomas as a group are rarely if ever curable and hence need chronic-disease management. New approaches to treatments are being investigated and include biological and cytotoxic drugs, phototherapy, and monoclonal antibodies that are directed towards novel molecular targets. New molecular technologies such as complementary-DNA microarray have the potential to increase the accuracy of diagnosis and provide important prognostic information. Treatments can be combined to greatly improve clinical outcome without substantially increasing toxic effects in advanced disease that is otherwise difficult to treat. Although present treatment strategies are generally not curative, there is hope that experimental treatments, particularly immunotherapy, might eventually reverse or suppress the abnormalities of mycosis fungoides and Sézary syndrome to the point at which they become non-life-threatening, chronic diseases.

AB - Mycosis fungoides and Sézary syndrome are the most common of the cutaneous T-cell lymphomas, which are a heterogeneous group of neoplasms that affect the skin as a primary site. Although the aetiologies of mycosis fungoides and Sézary syndrome are unknown, important insights have been gained in the immunological and genetic perturbations that are associated with these diseases. Unlike some B-cell lymphomas, cutaneous T-cell lymphomas as a group are rarely if ever curable and hence need chronic-disease management. New approaches to treatments are being investigated and include biological and cytotoxic drugs, phototherapy, and monoclonal antibodies that are directed towards novel molecular targets. New molecular technologies such as complementary-DNA microarray have the potential to increase the accuracy of diagnosis and provide important prognostic information. Treatments can be combined to greatly improve clinical outcome without substantially increasing toxic effects in advanced disease that is otherwise difficult to treat. Although present treatment strategies are generally not curative, there is hope that experimental treatments, particularly immunotherapy, might eventually reverse or suppress the abnormalities of mycosis fungoides and Sézary syndrome to the point at which they become non-life-threatening, chronic diseases.

UR - http://www.scopus.com/inward/record.url?scp=40649097522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40649097522&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(08)60420-1

DO - 10.1016/S0140-6736(08)60420-1

M3 - Review article

C2 - 18342689

AN - SCOPUS:40649097522

VL - 371

SP - 945

EP - 957

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9616

ER -